Findings

What do systematic reviews say?

240 questions · 244 findings · 23 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 39 · 16%GRADE not reported 15 · 6.1%Very low 78 · 32%Low 52 · 21.3%Moderate 49 · 20.1%High 11 · 4.5%

Eculizumab vs placebo or alternative treatment

Meningococcal infection · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Death · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Requirement for KRT · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

RISPERIDONE vs placebo

Aggression · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 238 participants
Low
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 190 participants
Moderate

RISPERIDONE vs placebo

Conduct · Disruptive behaviours in children and youths

1 finding from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 225 participants
Moderate

RISPERIDONE vs placebo

Weight gain · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 138 participants
Moderate
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

CHLORPROMAZINE vs OLANZAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 2.34 [1.37, 3.99]
3 studies · 204 participants
Low

CHLORPROMAZINE vs RISPERIDONE

QoL · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.11]
1 study · 41 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.06]
28 studies · 3241 participants
Moderate

CHLORPROMAZINE vs QUETIAPINE

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 548 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 8.03 [4.78, 13.51]
8 studies · 644 participants
Low

CHLORPROMAZINE vs QUETIAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.04 [0.77, 1.41]
12 studies · 1223 participants
Moderate

CHLORPROMAZINE vs OLANZAPINE

Relapse · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes relapse: long term (over 12 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.5 [0.46, 4.86]
1 study · 70 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 245 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 34.47 [4.79, 248.3]
2 studies · 298 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Health‐related quality of life (physical) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.69 [0.45, 6.4]
3 studies · 139 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

No significant clinical response ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in no significant clinical response ‐ short term (up to 6 months) compared with RISPERIDONE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.53, 1.34]
7 studies · 475 participants
Low